GET DAILY SIGNALSProKidney Corp. (PROK) Earnings Preview: Clinical Milestones Take Center Stage
Key Takeaways
- ProKidney Corp. (PROK) is expected to report third-quarter 2026 results around November 9–10, 2026, with a conference call scheduled for November 10 at 4:00 p.m. ET.
- Wall Street consensus points to a net loss of roughly $0.13 to $0.14 per share, alongside minimal revenue of approximately $0.12 million to $0.15 million.
- As a late clinical-stage cell therapy company, ProKidney remains essentially pre-revenue, so investors will focus on cash burn, research and development (R&D) spending, and clinical updates rather than top-line growth.
- The company recently completed enrollment for the Phase 3 PROACT 1 accelerated approval efficacy analysis, with pivotal eGFR (estimated glomerular filtration rate) slope topline results anticipated in Q2 2027.
- ProKidney's cash position of roughly $225 million is expected to fund operations into mid-2027, making capital-efficiency commentary a key watch item.
- For additional detail on the ticker's Major News, Today's Price Move, Price Targets, and Forecast, visit the dedicated ProKidney pages.
- Investors seeking broader market ideas can explore Trending AI Robots for additional trading insights.
Putting the Earnings in Context
ProKidney is advancing rilparencel (REACT), an autologous cell therapy for advanced chronic kidney disease (CKD) in patients with type 2 diabetes. Because the company generates almost no product revenue, its quarterly reports serve primarily as a gauge of clinical execution and financial runway. Prior quarters have shown disciplined spending, with R&D and general and administrative expenses trending lower year over year. The upcoming report arrives just months after the company completed enrollment for its Phase 3 PROACT 1 accelerated approval analysis and secured U.S. Food and Drug Administration (FDA) alignment on eGFR slope as a surrogate endpoint. For investors, the update offers a timely read on trial progress, expense control, and how long existing cash can sustain operations ahead of a pivotal data readout. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
What Analysts Are Expecting
Analysts expect ProKidney to report a net loss of approximately $0.13 to $0.14 per share for the third quarter of 2026, with consensus revenue of roughly $0.12 million to $0.15 million. A year earlier, in the third quarter of 2025, the company posted a net loss of $0.12 per share on revenue of about $0.22 million, reflecting the minimal, non-recurring nature of its revenue base.
More recent history shows mixed results against estimates. In the second quarter of 2026, ProKidney reported a loss of $0.15 per share, slightly missing the $0.14 consensus, while revenue of $0.15 million also came in below expectations. Given the company's pre-revenue profile, analysts and investors will weigh operating losses and cash consumption more heavily than the top line. Key metrics to watch include net loss before noncontrolling interest, R&D expense, and the cash, cash equivalents, and marketable securities balance at quarter end. From what I see, this is important because it highlights the focus on execution over revenue.
Market Reaction and Investor Sentiment
Sentiment heading into the report is shaped less by earnings estimates than by the clinical timeline. ProKidney's shares have traded well below their 52-week high as investors weigh the long gap until pivotal PROACT 1 data in Q2 2027 and the need to preserve capital. The recent completion of enrollment for the accelerated approval efficacy analysis was viewed as a positive de-risking step, though the stock has historically reacted modestly around earnings. Key risk factors include any signals of slower trial progress, higher-than-expected cash burn, or changes to the anticipated mid-2027 runway. Conversely, any incremental regulatory or enrollment clarity could support sentiment. I'm watching this closely as the data timeline unfolds.
Forward Outlook and Key Factors to Monitor
Following the third-quarter report, investors should watch several forward-looking themes. First is cash runway: ProKidney has guided that existing cash should fund operations into mid-2027, so any revision to that timeline would carry significant weight.
Second is execution on PROACT 1, the Phase 3 REGEN-006 study. With enrollment for the accelerated approval efficacy analysis complete, attention turns to whether the company remains on track for pivotal eGFR slope topline results in the second quarter of 2027. Management commentary on data-readout timing and any interim interactions with the FDA will be closely parsed.
Third is expense discipline. Recent quarters have shown lower R&D spending as earlier studies wind down, and investors will look for confirmation that this trend continues without compromising the registrational program. Finally, any updates on manufacturing readiness, RMAT (Regenerative Medicine Advanced Therapy) designation progress, or potential partnerships could shape the outlook.
As a pre-revenue biotech, ProKidney's near-term story hinges on clinical milestones and balance-sheet management rather than traditional earnings growth.
Using AI Tools for Deeper Analysis
In my view, staying on top of clinical-stage names like this requires efficient screening tools. I recently used Tickeron’s AI Screener to filter for similar biotech stocks based on volatility patterns and upcoming catalysts. It helped me quickly identify peers with comparable cash positions and trial timelines, giving a broader context without manual digging through filings. This kind of AI-assisted scan has become a regular part of how I prepare for reports like ProKidney’s, especially when the focus is on runway and milestone timing rather than earnings beats.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
PROK's Indicator enters downward trend
The Aroon Indicator for PROK entered a downward trend on November 09, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 184 similar instances where the Aroon Indicator formed such a pattern. In 161 of the 184 cases the stock moved lower. This puts the odds of a downward move at 88%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PROK as a result. In 75 of 99 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 76%.
The Moving Average Convergence Divergence Histogram (MACD) for PROK turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 54 similar instances when the indicator turned negative. In 42 of the 54 cases the stock turned lower in the days that followed. This puts the odds of success at 78%.
PROK moved below its 50-day moving average on October 12, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for PROK crossed bearishly below the 50-day moving average on October 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 18 of 21 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PROK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where PROK's RSI Oscillator exited the oversold zone, 23 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 55 of 69 cases where PROK's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
Following a +7.98% 3-day Advance, the price is estimated to grow further. Considering data from situations where PROK advanced for three days, in 202 of 257 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
PROK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 53 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.270) is normal, around the industry mean (3.498). P/E Ratio (-2.073) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (344.828) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. PROK’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PROK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement